(Q37866692)

24 August 2017

1 reference

title

Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors (English)

1 reference

24 August 2017

0 references

1 reference

Vincenza Andrisano

3

0 references

Francesca Mancini

series ordinal

1

object named as

Francesca Mancini

1 reference

24 August 2017

Angela De Simone

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

20 April 2011

1 reference

Analytical and Bioanalytical Chemistry

24 August 2017

published in

1 reference

24 August 2017

volume

400

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

1979-1996

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

24 August 2017

1 reference

Cellular mechanisms of beta-amyloid production and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Purification and cloning of amyloid precursor protein beta-secretase from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Four companies announce discovery of beta-secretase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Maturation and pro-peptide cleavage of beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Human β-Secretase (BACE) and BACE Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Progress in the discovery of BACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Human beta-secretase (BACE) and BACE inhibitors: progress report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Memapsin 2 (beta-secretase) inhibitors: drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Disease progression meta-analysis model in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Treatment of Alzheimer's disease: current status and new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Secretases as targets for the treatment of Alzheimer's disease: the prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE1 is the major beta-secretase for generation of Abeta peptides by neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Strategies for disease modification in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Design and Synthesis of Statine-Based Cell-Permeable Peptidomimetic Inhibitors of Human β-Secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Localization of beta-secretase memapsin 2 in the brain of Alzheimer's patients and normal aged controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Beta-secretase-cleaved amyloid precursor protein in Alzheimer brain: a morphologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Phosphorylation regulates intracellular trafficking of beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Assigning the protonation states of the key aspartates in β-Secretase using QM/MM X-ray structure refinement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Interaction models of substrate peptides and beta-secretase studied by NMR spectroscopy and molecular dynamics simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid Protein Production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Functional plasticity in the substrate binding site of beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Resonance energy transfer: methods and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Design of substrate-based inhibitors of human beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

A quenched fluorescent substrate for thimet peptidase containing a new fluorescent amino acid, DL-2-amino-3-(7-methoxy-4-coumaryl)propionic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE1- and BACE2-expressing human cells: characterization of beta-amyloid precursor protein-derived catabolites, design of a novel fluorimetric assay, and identification of new in vitro inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Design and characterization of a new cell-permeant inhibitor of the beta-secretase BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Development of a liquid chromatographic system with fluorescent detection for beta-secretase immobilized enzyme reactor on-line enzymatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

In silico discovery of beta-secretase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

A new specific BACE-1 inhibitor from the stembark extract of Vitis vinifera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structural basis for the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Designed Helical Peptides Inhibit an Intramembrane Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

An inhibitor binding pocket distinct from the catalytic active site on human beta-APP cleaving enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Highly sensitive intramolecularly quenched fluorogenic substrates for renin based on the combination of L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid with 2,4-dinitrophenyl groups at various positions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

The determination of specificity constants in enzyme-catalysed reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Efficiencies of fluorescence resonance energy transfer and contact-mediated quenching in oligonucleotide probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Mechanism of Inhibition of beta-site amyloid precursor protein-cleaving enzyme (BACE) by a statine-based peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Kinetic studies on beta-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Green tea catechins as a BACE1 (β-Secretase) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

A specific mechanism of nonspecific inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Effect of detergent on "promiscuous" inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Novel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Interpreting steep dose-response curves in early inhibitor discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

A continuous time-resolved fluorescence assay for identification of BACE1 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Targeting proteases: successes, failures and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Phe*-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Significance of interactions of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Blood-brain barrier active efflux transporters: ATP-binding cassette gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Bis(7)-tacrine, a novel acetylcholinesterase inhibitor, reverses AF64A-induced deficits in navigational memory in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Dual-target-directed 1,3-diphenylurea derivatives: BACE 1 inhibitor and metal chelator against Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Triazolyl tryptoline derivatives as β-secretase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

In vitro antiamyloidogenic properties of 1,4-naphthoquinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Rational approach to discover multipotent anti-Alzheimer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-011-4963-X

10.1007/S00216-011-4963-X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference